

**Forthcoming Papers in ANTICANCER RESEARCH** [ISSN (print): 0250-7005, ISSN (online): 1791-7530]

Analytical Anisotropic Algorithm *Versus* Pencil Beam Convolution for Treatment Planning of Breast Cancer: Implications for Target Coverage and Radiation Burden of Normal Tissue. A.M. FLEJMER, F. DOHLMAR, M. NILSSON, M. STENMARKER, A. DASU (Linköping; Jönköping, Sweden)

Radiation-induced Chondrosarcoma of the Bladder Case Report and Review of Literature. N. SULE, B. XU, D. EL ZEIN, K. SZIGETI, S. GEORGE, J.M. KANE, R. CHENEY (Buffalo, NY, USA)

Exosome-like Extracellular Vesicles from MYCN-amplified Neuroblastoma Cells Contain Oncogenic miRNAs. B.H. HAUG, Ø.H. HALD, P. UTNES, S.A. ROTH, C. LØKKE, T. FLÆGSTAD, C. EINVIK (Tromsø, Norway)

Down-regulation of Immune-related Genes by *PSCA* in Gallbladder Cancer Cells Implanted into Mice. N. SAEKI, H. ONO, H. SAKAMOTO, T. YOSHIDA (Tokyo, Japan)

Radiation-associated Cardiac Injury. R. EL DABAJE, D.L. LE, W. HUANG, L.-X. YANG (San Francisco, CA; Providence, RI, USA)

A New-Generation Fecal Immunochemical Test (FIT) is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia among Colonoscopy Referral Patients. S. VASILYEV, E. SMIRNOVA, D. POPOV, A. SEMENOV, C. EKLUND, P. HENDOLIN, L. PALOHEIMO, K. SYRJÄNEN (St. Petersburg, Russia; Helsinki, Finland; Barretos, SP, Brazil)

A Comparative Analysis of Breast and Ovarian Cancer-related Gene Mutations in Canadian and Saudi Arabian Patients with Breast Cancer. Y. AMEMIYA, S. BACOPULOS, M. AL-SHAWARBY, D. AL-TAMIMI, W. NASER, A. AHMED, M. KHALIFA, E. SLODKOWSKA, A. SETH (Toronto, ON, Canada; Dammam, Kingdom of Saudi Arabia)

Impact of Surgical Case Volume on the Accuracy of Preoperative Staging and Compliance with the Guidelines for the Management of Endometrial Cancer. M. KOSKAS, L. OULDAMER, N. BOURDEL, T. GAUTHIER, J.-L. BRUN, C. HUCHON (Paris; Tours; Clermont Ferrand; Limoges; Bordeaux; Poissy, France)

Early Reporting of Apoptosis by Real-time Imaging of Cancer Cells Labeled with Green Fluorescent Protein in the Nucleus and Red Fluorescent Protein in the Cytoplasm. M. YANG, P. JIANG, R.M. HOFFMAN (San Diego, CA, USA; Beijing, PR China)

Recent Developments in Radiosensitization. J. LINAM, L.-X. YANG (San Francisco, CA, USA)

Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer. T.H. ECKE, C. ARNDT, C. STEPHAN, S. HALLMANN, O. LUX, T. OTTO, J. RUTTLOFF, H. GERULLIS (Bad Saarow; Neuss; Berlin; Oldenburg, Germany)

Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-institutional Phase II Study. F. TRAMACERE, S. ARCANGELI, A. PIGNATELLI, R. CASTAGNA, M. PORTALURI (Brindisi; Rome; Pisa, Italy)

Targeted Therapy for NSCLC-A Double-edged Sword? W.C.M. DEMPKE (Munich, Germany)

Single-phase Whole-body 64-MDCT Split-bolus Protocol for Pediatric Oncology: Diagnostic Efficacy and Dose Radiation. M. SCIALPI, R. SCHIAVONE, A. D'ANDREA, I. PALUMBO, M. MAGLI, S. GRAVANTE, G. FALCONE, C. DE FILIPPI, B. PALUMBO (Perugia; Florence; Caserta; Parma, Italy)

Monofunctional Platinum-containing Pyridine-based Ligand Acts Synergistically in Combination with the Phytochemicals Curcumin and Quercetin in Human Ovarian Tumour Models. L. ARZUMAN, P. BEALE, J.Q. YU, F. HUQ (Lidcombe; Concord, NSW, Australia)

Gemcitabine Induces Radiosensitization through Inhibition of RAD51-dependent Repair for DNA Double-strand Breaks. S. KOBASHIGAWA, K. MORIKAWA, H. MORI, G. KASHINO (Oita; Fukuoka, Japan)

Para-aortic and Pelvic Radiotherapy, An Effective and Safe Treatment in Advanced-stage Uterine Cancer. A. RABINOVICH, L. BERNARD, T.M. NIAZI, A.V. RAMANAKUMAR, W.H. GOTLIEB, S. LAU, B. BAHORIC (Montreal, QC, Canada)

Significant Association of Cyclo-oxygenase 2 Genotypes with Upper Tract Urothelial Cancer. W.-S. CHANG, C.-H. LIAO, C.-M. HSU, C.-Y. HUANG, H.-Y. FANG, P.-Y. KAO, C.-W. TSAI, H.-C. WU, P.-S. HU, T.-C. WANG, Y.-R. SYU, H.-A. SHUI, D.-T. BAU (Taichung; Taipei; Changhua, Taiwan, ROC)

Demethoxycurcumin-induced DNA Damage Decreases DNA Repair-associated Protein Expression Levels in NCI-H460 Human Lung Cancer Cells. Y.-C. KO, J.-C. LIEN, H.-C. LIU, S.-C. HSU, H.-Y. LIN, F.-S. CHUEH, B.-C. JI, M.-D. YANG, W.-H. HSU, J.-G. CHUNG (Taichung; Changhua, Taiwan, ROC)

Relationships Between Dose Intensity, Toxicity, and Outcome in Patients with Oligodendrogial Tumors Treated with the PCV Regimen. E. TABOURET, G. REYES-BOTERO, C. DEHAIS, M. DAROS, M. BARRIE, M. MATTA, G. PETRIRENA, D. AUTRAN, A. DURAN, C. BEQUET, J.-Y. DELATTRE, O. CHINOT (Marseille; Paris, France)

Construction of a Model for Predicting Creatinine Clearance in Japanese Patients Treated with Cisplatin Therapy. A. YAJIMA, Y. UESAWA, C. OGAWA, M. YATABE, N. KONDO, S. SAITO, Y. SUZUKI, K. ATSUDA, H. KAGAYA (Minato; Kiyose; Meguro, Tokyo; Kashiwa, Chiba; Sagamihara, Kanagawa, Japan)

Differential Gene Expression of the Proto-oncogene VAV3 and the Transcript Variant VAV3.1 in Oral Squamous Cell Carcinoma. T. TRENKLE, S.G. HAKIM, H.-C. JACOBSEN, P. SIEG (Lübeck, Germany)

The Positive Interplay Between CD3<sup>+</sup> T-lymphocytes and Concurrent COX-2/EGFR Expression in Canine Malignant Mammary Tumors. M.I. CARVALHO, I. PIRES, J. PRADA, A.F. FERREIRA, F.L. QUEIROGA (Vila Real; Porto, Portugal; Sousa, PB, Brazil)

The Prognostic Role of Claudins -1 and -4 in Oral Squamous Cell Carcinoma. J.C. DE VICENTE, Á. FERNÁNDEZ-VALLE, B. VIVANCO-ALLENDE, T.R. SANTAMARTA, P. LEQUERICA-FERNÁNDEZ, G. HERNÁNDEZ-VALLEJO, E. ALLONCA-CAMPA (Oviedo; Madrid, Spain)

Amifostine Increases FAS and Caspase-3 Expression in Colonic Tissue of Irradiated Mice. C.T.F. OSHIMA, D.A. RIBEIRO, T.S. GOMES, P.C. ADIOS, M.I. EGAMI, H.R.C. SEGRETO (São Paulo, SP, Brazil)

Aberrant Differentiation of *Tsc2*-deficient Teratomas Associated with Activation of the mTORC1-TFE3 Pathway. H. KAWANO, Y. ITO, F. KANAI, E. NAKAMURA, N. TADA, S. TAKAI, S. HORIE, T. KOBAYASHI, O. HINO (Tokyo; Hiroshima, Japan)

Absolute Lymphocyte Count with Extreme Hyperleukocytosis Does not Have Prognostic Impact in Chronic Lymphocytic Leukemia. L. SHVIDEL, O. BAIREY, T. TADMOR, A. BRAESTER, R. RUCHLEMER, R. FINEMAN, E. JOFFE, A. BERREBI, A. POLLIACK, on behalf of the Israeli CLL Study Group (Jerusalem; Tel Aviv; Haifa; Ramat Gan; Beer Sheva, Israel)

Interleukin-32 Expression and Treg Infiltration in Esophageal Squamous Cell Carcinoma. B. NABEKI, S. ISHIGAMI, Y. UCHIKADO, K. SASAKI, Y. KITA, H. OKUMURA, T. ARIGAMI, Y. KIJIMA, H. KURAHARA, K. MAEMURA, S. NATSUGOE (Kagoshima, Japan)

Development and Validation of a Nomogram to Estimate the Risk of Prostate Cancer in Brazil. T.B. SILVA, C.Z. OLIVEIRA, E.F. FARIA, E.C. MAUAD, K.J. SYRJÄNEN, A.L. CARVALHO (Barretos, SP, Brazil; Helsinki, Finland)

Fast, Stable Induction of P-Glycoprotein-mediated Drug Resistance in BT-474 Breast Cancer Cells by Stable Transfection of *ABCB1* Gene. Y. TANG, Y. WANG, S. DEOSARKAR, F. SOROUGH, M.F. KIANI, B. WANG (Philadelphia; Wynnewood; Chester, PA, USA)

Analyzing Association of Polymorphisms in the CRYBB2 Gene with Prostate Cancer Risk in African Americans. M.U. FARUQUE, R. PAUL, L. RICKS-SANTI, E.Y. JINGWI, C.A. AHAGHOTU, G.M. DUNSTON (Washington, DC; Hampton, VA, USA)

Predictors of Intrahepatic Multiple Recurrences after Curative Hepatectomy for Hepatocellular Carcinoma. K. TAKEISHI, T. MAEDA, E. TSUJITA, Y.-I. YAMASHITA, N. HARADA, S. ITOH, N. HARIMOTO, T. IKEGAMI, T. YOSHIZUMI, K. SHIRABE, Y. MAEHARA (Fukuoka; Hiroshima, Japan)

Biochemical Action of New Complexes of Ruthenium with Quinolones as Potential Antitumor Agents. M.I. GRUIA, V. NEGOITA, M. VASILESCU, M. PANAIT, I. GRUIA, B.S. VELESCU, V. UIVAROSI (Bucharest, Romania)

The Role of Human Papilloma Virus in Urological Malignancies. I. HEIDEGGER, W. BORENA, R. PICHLER (Innsbruck, Austria)

Identification, Molecular Characterization and Alternative Splicing of Three Novel Members of the Canine Kallikrein (Klk)-related Peptidase Family. K. ANGELOPOULOU, G.S. KARAGIANNIS (Toronto, ON, Canada)

Aquaporin 3 Expression Predicts Survival in Patients with HER2-positive Early Breast Cancer. S. KANG, Y.S. CHAE, S.J. LEE, B.W. KANG, J.G. KIM, W.W. KIM, J.H. JUNG, H.Y. PARK, J.-H. JEONG, J.Y. JEONG, J.-Y. PARK (Daegu, Republic of Korea)

Expression of Formyl-peptide Receptors in Human Lung Carcinoma. F. CATTANEO, G. GUERRA, M. PARISI, A. LUCARIELLO, A. DE LUCA, N. DE ROSA, G. MAZZARELLA, A. BIANCO, R. AMMENDOLA (Naples; Campobasso, Italy)

Endoscopic Radiofrequency Ablation in Elderly Patients with Hepatocellular Carcinoma. K. DOI, T. BEPPU, T. ISHIKO, A. CHIKAMOTO, H. HAYASHI, K. IMAI, H. NITTA, Y. BABA, T. MASUDA, K. OKABE, M. KURAMOTO, K. KUDO, K. OGATA, T. OHCHI, H. TAKAMORI, K. KIKUCHI, H. BABA (Kumamoto; Miyazaki, Japan)

Phospholipase A2 Group III and Group X Have Opposing Associations with Prognosis in Colorectal Cancer. S. KAZAMA, J. KITAYAMA, M. HIYOSHI, Y. TAKETOMI, M. MURAKAMI, T. NISHIKAWA, T. TANAKA, J. TANAKA, T. KIYOMATSU, K. KAWAI, K. HATA, H. YAMAGUCHI, H. NOZAWA, S. ISHIHARA, E. SUNAMI, T. WATANABE (Tokyo, Japan)

Enhanced Antiproliferative and Pro-apoptotic Activities of a Novel Curcumin-related Compound in Jurkat Leukemia T-Cells. K. GOLDHAHN, M. HINTERSTEININGER, G. STEINER, T. ERKER, B. KLOESCH (Vienna, Austria)

Additional Surgery After Non-curative Resection of ESD for Early Gastric Cancer. T. KATSUBE, M. MURAYAMA, K. YAMAGUCHI, A. USUDA, A. SHIMAZAKI, S. ASAKA, S. KONNNO, A. MIYAKI, T. USUI, H. YOKOMIZO, S. SHIOZAWA, K. YOSHIMATSU, T. SHIMAKAWA, Y. NARITAKA (Tokyo, Japan)

No Significant Correlation of Clinical Outcomes Between First- and Second-line Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma. A. MIYAZAKI, H. MIYAKE, K.-I. HARADA, M. FUJISAWA (Kobe, Japan)

Recurrence 11 Years After Complete Response to Gemcitabine, 5-Fluorouracil, and Cisplatin Chemotherapy Followed by Radiotherapy in a Patient with Advanced Pancreatic Cancer: Report of a Case. T. UCHIHARA, Y.-I. YAMASHITA, W. HUALIN, K. TAKEISHI, S. ITOH, N. HARIMOTO, T. YOSHIZUMI, S. AISHIMA, K. SHIRABE, H. BABA, Y. MAEHARA (Fukuoka; Kumamoto; Saga, Japan)

Epithelial-mesenchymal-transition (EMT) Markers in Human Pituitary Adenomas Indicate a Clinical Course. W. JIA, J. ZHU, T.A. MARTIN, A. JIANG, A.J. SANDERS, W.G. JIANG (Beijing; YanTai, PR China; Cardiff, UK)

Impact of Nagasaki Atomic Bomb Exposure on Myelodysplastic Syndrome Patients who Are Treated with Azacitidine. T. JO, K. HORIO, K. SHIGEMATSU (Nagasaki, Japan)

Reduced UDP-glucose Levels Are Associated with P-glycoprotein Over-expression in L1210 Cells and Limit Glucosylceramide Synthase Activity. K. TURÁKOVÁ, L. PAVLÍKOVÁ, L. MESSINGEROVÁ, B. LAKATOŠ, A. BREIER, Z. SULOVIČ (Bratislava, Slovak Republic)

Profile of Serum Factors and Disseminated Tumor Cells Before and After Radiofrequency Ablation Compared to Resection of Colorectal Liver Metastases – A Pilot Study. S. HINZ, J. TEPEL, C. RÖDER, H. KALTHOFF, T. BECKER (Kiel; Osnabrück, Germany)

Kaempferol Is an Anti-Inflammatory Compound with Activity Towards NF- $\kappa$ B Pathway Proteins. O. KADIOGLU, J. NAß, M.E.M. SAEED, B. SCHULER, T. EFFERTH (Mainz; Freiburg, Germany)

Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome. J.Y. HONG, J.-Y. SEO, S.-H. KIM, H.A. JUNG, S. PARK, K. KIM, C.W. JUNG, J.S. KIM, J.S. PARK, H.-J. KIM, J.H. JANG (Seoul; Suwon, Republic of Korea)

The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel. A. BOURDOUMIS, M. CHRISOFOU, T. STASINO, P. CHRISTOPOULOS, P. MOURMOURIS, A. KOSTAKOPOULOS, C. DELIVELIOTIS (Torquay; Exeter, UK; Athens, Greece)

The Novel CA IX Inhibition Antibody chKM4927 Shows Anti-tumor Efficacy *In Vivo*. A. YAMAGUCHI, K. USAMI, M. SHIMABE, K. HASEGAWA, M. ASADA, K. MOTOKI, T. TAHARA, K. MASUDA (Tokyo, Japan)

Population-based Analysis of the Clinical Features of Primary Small Cell Carcinoma of the Ovary. O. JAMY, G. YAGHMOUR, F. HARE, M.G. MARTIN (Memphis, TN, USA)

Reduced Dose of Abiraterone Acetate with Concomitant Low Dose Prednisone in the Treatment of  $\geq 85$  Years Aged Patients with Advanced Castrate-resistant Prostate Cancer. R. PETRIOLI, E. FRANCINI, A.I. FIASCHI, L. LAERA, S.T. MIANO, G. DE RUBERTIS, G. ROVIELLO (Siena; Rome, Italy)

Contrast-enhanced Ultrasound Imaging of Antiangiogenic Tumor Therapy. L.V. KLOTZ, D.-A. CLEVERT, S. SCHECKINGER, S. STRIETH, M.E. EICHHORN (Munich; Mainz; Heidelberg, Germany)

Analyses of EGF A61G Gene Variation and Serum EGF Level on Gastric Cancer Susceptibility and Clinicopathological Parameters. C. CACINA, S. ARIKAN, Y. DÜZKÖYLÜ, M.B. DOĞAN, E. OKAY, S. TURAN, İ. YAYLIM, T. İSBİR (Istanbul; Kocaeli, Turkey)

Serum Angiopoietin-like Protein 2 Improves Preoperative Detection of Lymph Node Metastasis in Colorectal Cancer. Y. TOIYAMA, Y. INOUE, T. SHIMURA, H. FUJIKAWA, S. SAIGUSA, J. HIRO, M. KOBAYASHI, M. OHI, T. ARAKI, K. TANAKA, Y. MOHRI, M. KUSUNOKI (Mie, Japan)

High Dose Ionizing Radiation Regulates Gene Expression Changes in MCF7 Breast Cancer Cell Line. V. BRAVATÀ, L. MINAFRA, G. RUSSO, G.I. FORTE, F.P. CAMMARATA, M. RIPAMONTI, C. CASARINO, G. AUGELLO, F. COSTANTINI, G. BARBIERI, C. MESSA, M.C. GILARDI (Cefalù; Palermo; Milan; Monza, Italy)

Down-regulation of Phospholipase D Stimulates Death of Lung Cancer Cells Involving Up-regulation of the Long ncRNA *ANRIL*. Y.-H. KANG, D. KIM, E.-J. JIN (Iksan, Republic of Korea)

Combining CAL-101 with Celecoxib Enhances the Apoptosis of EBV-transformed B-Cells Through MAPK-induced ER Stress. G.B. PARK, D.Y. HUR, D. KIM (Busan, Republic of Korea)

Simultaneous Integrated Boost (SIB): RapidArc and Tomotherapy Plan Comparison for Unilateral and Bilateral Neck Irradiation. C. STROMBERGER, W. WLODARCZYK, S. MARNITZ, B. JAMIL, V. BUDACH, J.-D. RAGUSE, A. BOETTCHER, H. BADAKHSHI (Berlin; Oder, Germany)

Differential MicroRNA Expression Profiles in Primary and Recurrent Epithelial Ovarian Cancer. G.O. CHONG, H.-S. JEON, H.S. HAN, J.W. SON, Y.H. LEE, D.G. HONG, Y.S. LEE, Y.L. CHO (Daegu; Daejeon, Republic of Korea)

Class III Beta-tubulin Expression in Non-small Cell Lung Cancer: A Predictive Factor for Paclitaxel Response. T. OHASHI, T. YOSHIMASU, S. OURA, Y. KOKAWA, M. KAWAGO, Y. HIRAI, M. MIYASAKA, Y. AOISHI, M. KIYOI, H. NISHIGUCHI, M. HONDA, Y. OKAMURA (Wakayama, Japan)

Imaging the Interaction of Pancreatic Cancer and Stellate Cells in the Tumor Microenvironment During Metastasis. A. SUETSUGU, C.S. SNYDER, H. MORIWAKI, S. SAJI, M. BOUVET, R.M. HOFFMAN (San Diego, CA, USA; Gifu, Japan)

Radiosurgery or Fractionated Stereotactic Radiotherapy plus Whole Brain Radiotherapy in Brain Oligometastases: A Long-term Analysis. M. BALDUCCI, R. AUTORINO, S. CHIESA, G. MATTIUCCI, A. POMPUCCI, L. AZARIO, G.R. D'AGOSTINO, M. FERRO, A. FIORENTINO, S. FERSINO, C. MAZZARELLA, C. COLOSIMO, V. FRASCINO, C. ANILE, V. VALENTINI (Rome, Italy)

Lupalbigenin from *Derris scandens* Sensitizes Detachment-induced Cell Death in Human Lung Cancer Cells. A. AUSAWASAMRIT, N. ITTHIWARAPORNKUL, C. CHAOTHAM, S. SUKRONG, P. CHANVORACHOTE (Bangkok, Thailand)

Nuclear Survivin Expression in Small Cell Lung Cancer. Y. YANO, T. OTSUKA, H. HIRANO, T. UENAMI, A. SATOMI, M. KUROYAMA, M. NIINAKA, T. YONEDA, H. KIMURA, M. MORI, T. YAMAGUCHI, S. YOKOTA (Osaka, Japan)

A New Strategy for Metachronous Primary Lung Cancer: Stereotactic Body Radiation Therapy with Concurrent Chemotherapy. J. TAKESHITA, K. MASAGO, R. KATO, K. OTSUKA, C. OKUDA, A. HATA, R. KAJI, S. FUJITA, K. TAKAYAMA, M. KOKUBO, N. KATAKAMI (Kobe, Japan)

Differential Gene Regulation in Fibroblasts in Coculture with Keratinocytes and Head and Neck SCC Cells. M. HAKELIUS, D. SAEIPOUR, H. GÖRANSSON, K. RUBIN, B. GERDIN, D. NOWINSKI (Uppsala, Sweden)

Randomized Trials of Systemic Medically Treated Malignant Mesothelioma: A Systematic Review. C. BLOMBERG, J. NILSSON, G. HOLGERSSON, P. EDLUND, M. BERGQVIST, L. ADWALL, S. EKMAN, D. BRATTSTRÖM, S. BERGSTRÖM (Gävle; Uppsala; Gävleborg; Umeå, Sweden)

The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. Ş. COMŞA, A.M. CÎMPEAN, M. RAICA (Timișoara, Romania)

Significance of Hepatectomy for AJCC/UICC T3 Hepatocellular Carcinoma. T. OCHIAI, H. ISHII, Y. YAMAMOTO, R. MORIMURA, H. IKOMA, E. OTSUJI (Kyoto, Japan)

Thymidine Kinase Levels Correlate With Prognosis in Aggressive Lymphoma and Can Discriminate Patients with a Clinical Suspicion of Indolent to Aggressive Transformation. M.E. GATT, N. GOLDSCHMIDT, I. KALICHMAN, M. FRIEDMAN, A.C. ARRONSON, V. BARAK (Jerusalem, Israel)

Does the Diagnosis Center Influence the Prognosis of Ovarian Cancer Patients Submitted to Neoadjuvant Chemotherapy? G. VIZIELLI, F. FANFANI, V. CHIANTERA, L. TORTORELLA, A. LUCIDI, M. PETRILLO, B. COSTANTINI, G. SCAMBIA, A. FAGOTTI (Rome; Campobasso; Terni, Italy)

Effect of New Oxicam Derivatives on Efflux Pumps Overexpressed in Resistant Human Colorectal Adenocarcinoma Cell Line. K. ŚRODA-POMIANEK, O. WESOŁOWSKA, B. SZCZEŚNIAK-SIĘGA, B. PUŁA, P. DZIĘGIEL, J. MANIEWSKA, W. MALINKA, A. PALKO-ŁABUZ, K. MICHALAK (Wrocław, Poland)

Sensitivity of Neoplastic Cells to Senescence Unveiled Under Standard Cell Culture Conditions. J. ZIEBA, M. KSIAZKIEWCZ, K. JANIK, M. BANASZCZYK, J. PECIAK, S. PIASKOWSKI, M. LIPINSKI, M. OLCZAK, E. STOCZYNSKA-FIDELUS, P. RIESKE (Lodz, Poland)

Pentraxin-3 Silencing Suppresses Gastric Cancer-related Inflammation by Inhibiting Chemotactic Migration of Macrophages. B. CHOI, E.-J. LEE, Y.S. PARK, S.-M. KIM, E.-Y. KIM, Y. SONG, S.-W. KANG, M.-H. RHU, E.-J. CHANG (Seoul, Republic of Korea)

Induction Chemotherapy Using FAP for Patients with Stage II/III Squamous Cell Carcinoma of the Esophagus. S. TAMURA, A. TAKENO, H. TANIGUCHI, Y. KATSURA, Y. OHMURA, Y. KAGAWA, H. SAKISAKA, Y. TAKEDA, T. KATO (Hyogo, Japan)

Uniform Combretastatin-induced Effect on Monocytes and Neutrophils in Peripheral Blood but Not in Tumors. A.B. BOHN, A.S. BREMS-ESKILDSEN, B.K. MØLLER, M.R. HORSMAN (Aarhus, Denmark)

Sentinel Node Navigation Surgery for Lower Rectal Cancer. H. KAWAHARA, K. WATANABE, H. ENOMOTO, M. TOMODA, T. AKIBA, K. YANAGA (Chiba; Tokyo, Japan)

Azaspirene Analogs Inhibit the Growth of Human Uterine Carcinosarcoma *In Vitro* and *In Vivo*. M. EMOTO, K. YANO, B. CHOIJAMTS, S. SAKAI, S. HIRASAWA, S. WAKAMORI, M. AIZAWA, K. NABESHIMA, K. TACHIBANA, N. KANOMATA (Fukuoka; Tokyo; Kawasaki, Japan)

<sup>18</sup>F-FDG-PET/CT Imaging in Patients with Febrile Neutropenia and Haematological Malignancies. V. CAMUS, A. EDET-SANSON, M. BUBENHEIM, A. HITZEL, S. BECKER, M. DAVID, A. STAMATOULLAS, P. LENAIN, F. JARDIN, N. CONTENTIN, M.L. FONTOURA, N. CARDINAEL, S. VAUDAUX, S. DUBOIS, H. TILLY, P. VERA, S. LEPRÊTRE (Rouen; Toulouse, France)

Radiation Therapy for Choroid Plexus Carcinoma Patients with Li-Fraumeni Syndrome: Advantageous or Detrimental? M. BAHAR, U. KORDES, T. TEKAUTZ, J. WOLFF (Cleveland, OH, USA; Hamburg, Germany)

The Use of Living Cancer Cells Expressing Green Fluorescent Protein in the Nucleus and Red Fluorescence Protein in the Cytoplasm for Real-time Confocal Imaging of Chromosome Dynamics and Cytokinesis During Mitosis. A. SUETSUGU, P. JIANG, M. YANG, N. YAMAMOTO, H. MORIWAKI, S. SAJI, R.M. HOFFMAN (San Diego, CA, USA; Gifu; Kanazawa, Japan; Beijing, PR China)

MCPI-Induced Epithelial-Mesenchymal Transition in Head and Neck Cancer by AKT Activation. C.-C. LEE, H.-C. HO, Y.-C. SU, M.-S. LEE, S.-K. HUNG, C.-H. LIN (Chiayi; Hualian, Taiwan, ROC)

Rare Complex Mutational Profile in an ALK Inhibitor-resistant Non-small Cell Lung Cancer. E.M. AZZATO, C. DESHPANDE, V. AIKAWA, C. AGGARWAL, E. ALLEY, B. JACOBS, J. MORRISSETTE, R. DABER (Philadelphia, PA, USA)

Circulating Tumour Cells in Patients with Malignant Lung Tumours Undergoing Radio-frequency Ablation. D. CHUDASAMA, A. RICE, V. ANIKIN, G. SOPPA, P. DALAL (Harefield, Middlesex, UK)

Cerebral Relapsing Meningioma: A Surgical Series with Lack of Reliability of Standard Parameters Establishing Prognosis. F. FOREST, V. YVOREL, F. VASSAL, B. TROMBERT, J.-M. DUMOLLARD, C. NUTI, M. PÉOCH (Saint Étienne, France)

Induction of G1 Arrest by SB265610 Involves Cyclin D3 Down-regulation and Suppression of CDK2 (Thr160) Phosphorylation. A.E. GODA, R.L. ERIKSON, J.-S. AHN, B.-Y. KIM (Cheongwon, Republic of Korea; Cambridge, MA, USA; Tanta, Egypt)

Endothelial Cells Derived from Non-malignant Tissues Are of Limited Value as Models for Brain Tumor Vasculature. J. LOHR, A. MOCK, P. BECKHOVE, C. HEROLD-MENDE (Heidelberg, Germany)

Microarray Analysis Reveals Distinct Gene Set Profiles for Gastric And Intestinal Gastrointestinal Stromal Tumors. R. HARA, H. KIKUCHI, T. SETOGUCHI, S. MIYAZAKI, M. YAMAMOTO, Y. HIRAMATSU, K. KAMIYA, M. OHTA, S. BABA, H. KONNO (Hamamatsu, Japan)

Impact of the Stereotactic Radiosurgery Dose on the Control of Cerebral Metastases from Renal Cell Carcinoma. D. RADES, S. HUTTENLOCHER, N. GEBAUER, D. HORNING, N.T. TRANG, M.T. KHOA, S.E. SCHILD (Lübeck; Hamburg, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA)

Serrated Adenoma of the Gallbladder - Case Report. C.A. RUBIO (Stockholm, Sweden)

MicroRNA-145 Promotes the Phenotype of Human Glioblastoma Cells Selected for Invasion. S. KOO, G. MARTIN, L.G. TOUSSAINT (Bryan, TX, USA)

The Impact of Perioperative Allogeneic Blood Transfusion on Survival in Elderly Patients with Colorectal Cancer. M. KANEKO, S. SASAKI, K. ISHIMARU, E. TERAI, H. NAKAYAMA, T. WATANABE (Tokyo, Japan)

Telomere Length Abnormalities and Telomerase RNA Component Expression in Gastroenteropancreatic Neuroendocrine Tumors. H.S. KIM, H.S. LEE, K.H. NAM, J. CHOI, W.H. KIM (Seoul; Gyeonggi-do; Busan, Republic of Korea)

Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer. C. DAMASKOS, T. KARATZAS, L. NIKOLIDAKIS, I.D. KOSTAKIS, S. KARAMAROUDIS, G. BOUTSIKOS, Z. DAMASKOU, A. KOSTAKIS, G. KOURAKLIS (Athens, Greece)

Inflammation-Related Tumor Progression in Murine Fibrosarcoma Exhibited Over-expression of Sex-determining region Y-box 2 (Sox2) Compared to Parental Regressor Cells. Y. KURAMITSU, I. TANAKA, Y. WANG, F. OKADA, K. TOKUDA, T. KITAGAWA, J. AKADA, K. NAKAMURA (Ube; Shunan, Yamaguchi; Yonago; Japan)

Duration of First-line Treatment with Molecular Targeted Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma. K. UEDA, S. SUEKANE, K. NISHIHARA, N. OGASAWARA, H. KUROSE, S. HAYASHI, K. CHIKUI, S. SUYAMA, M. NAKIRI, M. MATSUO, T. IGAWA (Fukuoka, Japan)

A Cohort Study Evaluating the Role of Surgery for Lung Metastases from Colorectal Cancer. F. SOCOLA, D.M. NGUYEN, R.E. OCHOA, C.M. ROCHA LIMA, P.J. HOSEIN (Little Rock, AR; Miami, FL; Lexington, KY, USA)

Reversal of ABCB1-related Multidrug Resistance of Colonic Adenocarcinoma Cells by Phenothiazines. D. TAKÁCS, Á. CSONKA, Á. HORVÁTH, T. WINDT, M. GAJDÁCS, Z. RIEDL, G. HAJÓS, L. AMARAL, J. MOLNÁR, G. SPENGLER (Budapest; Szeged, Hungary; Lisbon, Portugal)

Liver Transplantation Followed by Pulmonary Resection Complicated With End-Stage Liver Cirrhosis: A Case Report. D. TANIGUCHI, N. HARIMOTO, K. TAKEISHI, S. ITOH, Y. YAMASHITA, T. IKEGAMI, T. YOSHIZUMI, H. KAWANAKA, K. SHIRABE, Y. MORODOMI, T. TAGAWA, T. OKAMOTO, Y. MAEHARA (Fukuoka, Japan)

Second Primary Malignancies in Mantle Cell Lymphoma: A U.S. Population-based Study. B.K. SHAH, A. KHANAL (Chicago, IL, USA)

Short-term Survival of Patients with Lung Metastases from Colorectal and Non-colorectal Cancer who Underwent Pulmonary Metastasectomy. F. LUMACHI, F. MAZZA, A. DEL CONTE, G. LO RE, M. ERMANI, G.B. CHIARA, S.M.M. BASSO (Padova; Pordenone, Italy)

Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics. R. KUCERA, O. TOPOLCAN, I. TRESKOVA, J. KINKOROVA, J. WINDRICOVA, R. FUCHSOVA, S. SVOBODOVA, V. TRESKA, V. BABUSKA, J. NOVAK, J. SMEJKAL (Prague, Czech Republic)

Significance of Lymphatic Invasion Combined with Size of Primary Tumor for Predicting Sentinel Lymph Node Metastasis in Patients with Breast Cancer. T. FUJII, R. YAJIMA, H. TATSUKI, T. SUTO, H. MORITA, S. TSUTSUMI, H. KUWANO (Maebashi, Gunma, Japan)

Correlation of *HIWI* and *HILI* Expression with Cancer Stem Cell Markers in Colorectal Cancer. M. LITWIN, J. DUBIS, K. ARCZYŃSKA, A. PIOTROWSKA, A. FRYDLEWICZ, M. KARCEWSKI, P. DZIĘGIEL, W. WITKIEWICZ (Wrocław, Poland)

Atypical Paracaval Recurrence of Uterine Endometrial Stromal Sarcoma – A Case Report. N. BACALBASA, I. BALESCU (Bucharest, Romania)

Frequent High Expression of Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1) in Gastric Cancer. A. SHIDA, N. FUTAWATARI, T. FUKUYAMA, Y. ICHIKI, Y. TAKAHASHI, Y. NISHI, N. KOBAYASHI, H. YAMAZAKI, M. WATANABE (Kitamoto, Saitama; Kitakyushu, Fukuoka; Sagami, Kanagawa, Japan)

Suicidal Ideation *Versus* Hopelessness/Helplessness in Healthy Individuals and in Patients with Benign Breast Disease and Breast Cancer: A Prospective Case-control Study in Finland. M. ESKELINEN, R. KORHONEN, T. SELANDER, P. OLLONEN (Kuopio, Finland)

PSA Isoforms' Velocities for Early Diagnosis of Prostate Cancer. I. HEIDEGGER, H. KLOCKER, R. PICHLER, W. HORNINGER, J. BEKTIC (Innsbruck, Austria)

Circulating Cytokine Levels in Patients with Prostate Cancer: Effects of Neoadjuvant Hormonal Therapy and External Beam Radiotherapy. N. TANJI, T. KIKUGAWA, T. OCHI, S. TAGUCHI, H. SATO, T. SATO, T. SUGAHARA, H. HAMADA, S. ASAI, A. MATSUMOTO (Ehime, Japan)

Local Therapy Improvement of Outcome in a Patient with Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation: Case Report. M. SHIMOKAWA, S. ITOH, T. IKEGAMI, K. TAKEISHI, N. HARIMOTO, Y.-I. YAMASHITA, T. YOSHIZUMI, H. KAWANAKA, K. SHIRABE, Y. MAEHARA (Fukuoka, Japan)

Multicenter Randomized Phase II Study of Weekly Docetaxel *Versus* Weekly Docetaxel plus Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer. J.Y. KIM, H.M. RYOO, S.H. BAE, B.W. KANG, Y.S. CHAE, S. YOON, J.H. BAEK, M.K. KIM, K.H. LEE, S.A. LEE, H.S. SONG, J.G. KIM (Daegu, Republic of Korea)

Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: The Results from Czech Observational Registry. I. KOCAKOVA, B. MELICHAR, I. KOCAK, Z. BORTLICEK, T. BÜCHLER, L. DUSEK, L. PETRUZELKA, M. KOHOUTEK, J. PRAUSOVÁ, J. FINEK, B. MOHELNIKOVA-DUCHONOVA, R. VYZULA (Brno; Olomouc; Prague; Zlin; Plzen, Czech Republic)

ROCK I Has More Accurate Prognostic Value than MET in Predicting Patient Survival in Colorectal Cancer. J. LI, S.S. BHARADWAJ, G. GUZMAN, R. VISHNUHOTLA, S.C. GLOVER (Gainesville, FL; Chicago, IL, USA)

Retrospective Analysis of Concurrent Chemoradiation with Triweekly Cisplatin plus 5-Fluorouracil Versus Weekly Cisplatin in Cervical Cancer. K. SONODA, H. YAHATA, A. ICHINOE, K. OKUGAWA, E. KANEKI, Y. KAWANO, H. KENJO, T. OHGAMI, H. YAGI, S. OHGA, K. ASAI, K. NAKAMURA, H. HONDA, K. KATO (Fukuoka, Japan)

Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly ( $\geq 75$  Years) Patients. G.-C. MATTIUCCI, M. FALCONI, R.G.P.M. VAN STIPHOUT, S. ALFIERI, F.A. CALVO, J.M. HERMAN, B.W. MAIDMENT III, R.C. MILLER, W.F. REGINE, M. RENI, N. SHARMA, S. PARTELLI, D. GENOVESI, M. BALDUCCI, F. DEODATO, V. VALENTINI, A.G. MORGANTI (Rome; Verona; Milan; Ancona; Chieti; Campobasso, Italy; Maastricht, Netherlands; Madrid, Spain; Baltimore, MD; Charlottesville, VA; Rochester, NY, USA)

Differential Genome Damage in Different Tumor Lines Induced by Prodigiosin. J.C. LAPENDA, M.E.B. MELO, S.C. NASCIMENTO, M.L. ADAM (Recife, PE; Pernambuco, Brazil)

Gene Expression Profiling of MCF10A Breast Epithelial Cells Exposed to IOERT. L. MINAFRA, V. BRAVATÀ, G. RUSSO, G.I. FORTE, F.P. CAMMARATA, M. RIPAMONTI, G. CANDIANO, M. CERVELLO, A. GIALLONGO, G. PERCONTI, C. MESSA, M.C. GILARDI (Cefalù; Palermo; Milan; Monza, Italy)

PDGFR- $\alpha$  and CD117 Expression Pattern in Esophageal Carcinomas. M.A. GOSCINSKI, S.G. LARSEN, K.-E. GIERCKSKY, J.M. NESLAND, Z. SUO (Oslo, Norway)

Obesity and Lymphovascular Invasion in Women with Uterine Endometrioid Carcinoma. M. KAMAL, C. BURMEISTER, Z. ZHANG, A. MUNKARAH, M.A. ELSHAIKH (Detroit, MI, USA)

Effective Treatment of Transmissible Veneral Tumors (TVT) in Dogs with Vincristine + IL-2. W. DEN OTTER, M. HACK, J.J.L. JACOBS, J.F.V. TAN, L. ROZENDAAL, R.J. VAN MOORSELAAR (Amsterdam; Gouda, The Netherlands; Rondeklip, Curacao)

Expression and Tissue Distribution of MicroRNA-21 in Malignant and Benign Breast Tissues. K.A. HUG, L. ANTHONY, D. ELDEIRY, J. BENSON, E. WHEELER, S. MOUSA, B. SHI (Albany; Troy, NY, USA)

## Instructions to Authors 2015

*General Policy.* ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

*NIH Open Access Policy.* The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

*Copyright.* Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

*Format.* Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

*Manuscripts.* Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

*Figures.* All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

*Tables.* Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

*References.* Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.



*Nomenclature and Abbreviations.* Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

*Clinical Trials.* Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

*Ethical Policies and Standards.* ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

*Submission of Manuscripts.* Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (\*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios  
International Institute of Anticancer Research (IIAR)  
Editorial Office of ANTICANCER RESEARCH,  
IN VIVO, CANCER GENOMICS and PROTEOMICS.  
1st km Kapandritiou-Kalamou Road  
P.O. Box 22, GR-19014 Kapandriti, Attiki  
GREECE

Submitted articles will not be returned to Authors upon rejection.

*Galley Proofs.* Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2015 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

# CANCER GENOMICS & PROTEOMICS

www.cgp.iarjournals.org

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)  
From VOL. 10 (2013) online – only and open access



International Online **Open Access** Journal

**General Policy.** CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**. For more information please visit our website [www.cgp.iarjournals.org](http://www.cgp.iarjournals.org).

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. E-mail: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org); IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iarjournals.org](http://www.iarjournals.org)

## A Selection of Recent Articles

The Metastasis Suppressor NME1 Regulates Expression of Genes Linked to Metastasis and Patient Outcome in Melanoma and Breast Carcinoma. J.R. MCCORKLE, M.K. LEONARD, S.D. KRANER, E.M. BLALOCK, D. MA, S.G. ZIMMER, D.M. KAETZEL (*Memphis, TN; Baltimore, MD; Lexington, KY; Iowa City, IA, USA*)

Profiling of Chromosomal Changes in Potentially Malignant and Malignant Oral Mucosal Lesions from South and South-East Asia Using Array-Comparative Genomic Hybridization. M.L.S. LUNDE, E. ROMAN, S. WARNAKULASURIYA, R. MEHROTRA, J. LARANNE, E.N. VASSTRAND, S.O. IBRAHIM (*Bergen, Norway; London, UK; Allahabad, India; Tampere, Finland*)

Expression of Claudins in Human Clear Cell Renal Cell Carcinoma. W. MEN, T.A. MARTIN, F. RUGE, N. ZHANG, P. DU, Y. YANG, W.G. JIANG (*Beijing, China; Cardiff, UK*)

TCR-MHC/Peptide Interaction: Prospects for New Anti-tumoral Agents. U.H. WEIDLE, G. GEORGES, G. TIEFENTHALER (*Penzberg, Germany*)

Modulation of Liver-Intestine Cadherin (Cadherin 17) Expression, ERK Phosphorylation and WNT Signaling in EPHB6 Receptor-expressing MDA-MB-231 Cells. L. BHUSHAN, N. TAVITIAN, D. DEY, Z. TUMUR, C. PARSA, R.P. KANDPAL (*Pomona, CA, USA*)

Phenome-Genome Association Studies of Pancreatic Cancer: New Targets for Therapy and Diagnosis. R. NARAYANAN (*Boca Raton, FL, USA*)

Usefulness of Nanofluidic Digital PCR Arrays to Quantify T790M Mutation in EGFR-mutant Lung Adenocarcinoma. K. ISOBE, Y. HATA, N. TOCHIGI, K. KABURAKI, H. KOBAYASHI, T. MAKINO, H. OTSUKA, F. ISHIDA, N. HIROTA, G. SANO, K. SUGINO, S. SAKAMOTO, Y. TAKAI, K. SHIBUYA, A. IYODA, S. HOMMA (*Tokyo, Japan*)

Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Lung Adenocarcinoma. S.A. ALMATROODI, C.F. MCDONALD, A.L. COLLINS, I.A. DARBY, D.S. POUNIOTIS (*Bundoora; Heidelberg, VIC, Australia; Buraidah, Saudi Arabia*)

Metabolic profile of Triple-negative Breast Cancer in African-American Women Reveals Potential Biomarkers of Aggressive Disease. Y.M. KANAAN, B.P. SAMPEY, D. BEYENE, A.K. ESNAKULA, T.J. NAAB, L.J. RICKS-SANTI, S. DASI, A. DAY, K.W. BLACKMAN, W. FREDERICK, R.L. COPELAND, E. GABRIELSON, R.L. DEWITTY JR. (*Washington DC; Durham, NC; Cleveland, OH; Hampton, VA; Baltimore, MD, USA*)

Analysis of SHOX2 Methylation as an Aid to Cytology in Lung Cancer Diagnosis. P. ILSE, S. BIESTERFELD, N. POMJANSKI, C. WROBEL, M. SCHRAMM (*Düsseldorf, Germany*)

The Role of Apurinic/Apyrimidinic Endonuclease DNA Repair Gene in Endometriosis. C.-M. HSU, W.-S. CHANG, J.-J. HWANG, J.-Y. WANG, Y.-L. HSIAO, C.-W. TSAI, J.-C. LIU, T.-H. YING, D.-T. BAU (*Taichung; Taipei, Taiwan, ROC*)

Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma. A. BOTEZATU, C. BLEOTU, A. NASTASE, G. ANTON, N. BACALBASA, D. DUDA, S.O. DIMA, I. POPESCU (*Bucharest, Romania; Charlestown, MA, USA*)

# in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

## General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org) and [www.iv.iiarjournals.org](http://www.iv.iiarjournals.org)

## Selection of Recent Articles

Effect of Radiation and Repeated Sub-culturing on the Transforming Growth Factor- $\beta$ 1 Signaling Pathway in FRTL-5 Cells. C.G. BURRELL, D.S. GRIDLEY, L.S. ORTLOFF, S.M. CHARLES, L.M. GREEN (*Loma Linda, CA; Winston-Salem, NC, USA*)

IL6 Plasma Concentrations in Patients with Sepsis Receiving SLED and Antibiotics: A Predictor for Survival. T.R. MCGUIRE, N.T. REARDON, K. BOGARD, T.J. PLUMB, C.J. BULTSMA, S.W. NISSEN, P.D. FULLER, K.M. OLSEN (*Omaha, NE; Ocala, FL, USA*)

Organ-specific Responses of Total Body Irradiated Doxycycline-inducible Manganese Superoxide Dismutase Tet/Tet Mice. B.H. RHIEU, A. SHINDE, M.W. EPPERLY, T. DIXON, H. WANG, R. CHAILLET, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Effect of GPIIb/IIIa Inhibition with Eptifibatid or Tirofiban on the Expression of Cellular Adhesion Molecules on Monocytes. S. SWOBODA, T. WALTER, S. LANG, H.-P. WENDEL, M.E. BEYER, E. GRIESEL, H.-M. HOFFMEISTER, J. GRUETTNER (*Heidelberg; Tuebingen; Kirchheim; Solingen, Germany*)

Tolerated Doses in Zebrafish of Cytochalasins and Jasplakinolide for Comparison with Tolerated Doses in Mice in the Evaluation of Pre-clinical Activity of Microfilament-directed Agents in Tumor Model Systems *In Vivo*. M. TRENDOWSKI, V. WONG, K. WELLINGTON, S. HATFIELD, T.P. FONDY (*Syracuse, NY, USA*)

A Novel Role of CYP2E1 in Human Megakaryocyte Development. Y. TANG, G. ZHANG, M. BAIRD, F. RACKE, W. ZHAO (*Columbus, OH; San Juan Capistrano, CA, USA*)

Efficacy and Side Effects of a Semi-individualized Chinese Herb Mixture "Tiáo Gēng Tāng" for Menopausal Syndrome in China. M. JIA, L. KLUWE, H.-C. LIU, Q.-J. TANG, L. LIU, Z.-Z. WANG, L.-X. TIAN, L. ZHAO, Y.-C. CHEN, R.E. FRIEDRICH, Z.-J. SUN, L.-W. XU (*Shanghai, PR China; Hamburg, Germany*)

Sex Hormones Differentially Modulate STAT3-dependent Antioxidant Responses during Oxidative Stress in Renal Proximal Tubule Cells. D.K. REED, I. ARANY (*Jackson, MS, USA*)

Effect of Melatonin on Human Nighttime Endotoxaemia: Randomized, Double-blinded, Cross-over Study. M. ALAMILI, K. BENDTZEN, J. LYKKESFELDT, J. ROSENBERG, I. GÖGENUR (*Køge; Copenhagen; Herlev, Denmark*)

The Success Rate in a Complicated Spatial Memory Test Is Determined by Age, Sex, Life History and Search Strategies in Cynomolgus Monkeys. H.S. DARUSMAN, O. KALLIOKOSKI, D. SAJUTHI, S.J. SCHAPIRO, A. GJEDDE, J. HAU (*Copenhagen; Aarhus, Denmark; Bogor, Indonesia; Bastrop, TX; Baltimore, MD, USA; Montréal, QC, Canada*)

No Changes in Cerebral Microcirculatory Parameters in Rat During Local Cortex Exposure to Microwaves. H. MASUDA, S. HIROTA, A. USHIYAMA, A. HIRATA, T. ARIMA, H. WATANABE, K. WAKE, S. WATANABE, M. TAKI, A. NAGAI, C. OHKUBO (*Tokyo; Saitama; Aichi, Japan*)

Improving the Bioavailability and Anticancer Effect of the PCA-1/ALKBH3 Inhibitor HUHS015 Using Sodium Salt. M. MABUCHI, T. SHIMIZU, M. UEDA, Y. SASAKAWA, S. NAKAO, Y. UEDA, A. KAWAMURA, K. TSUJIKAWA, A. TANAKA (*Kobe; Osaka; Suita; Kainan, Japan*)

CAG-repeats in Androgen Receptor Gene Relate with Plasma Androgens Levels in the Bouvier Des Flandres. H. L' EPLATTENIER, E. TESKE, F. VAN SLUIJS, J.A. MOL (*Utrecht, Netherlands*)

Bone Substitutes Enhance Osteogenic Differentiation of Mesenchymal Stem Cells in Three-dimensional Scaffolds. H. HANKEN, J. ALPERS, M. BÖBEL, M. WÖLTJE, P. HARTJEN, R.E. FRIEDRICH, O. JUNG, C. RENDENBACH, A. GRÖBE, M. HEILAND, A. AL-DAM, W. EICHHORN, R. SMEETS (*Hamburg; Aachen, Germany*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

# Subscription Order Form 2015

- Please enter a Subscription to ANTICANCER RESEARCH Volume 35 (2015).  
Annual subscription rates (2015): Institutional, Euro 1,650.00 print or online; Personal, Euro 780.00 print or online;  
Prices include rapid delivery and insurance.  
2015 online subscriptions include free online access to vol. 24 (2004) - 34 (2014).
- Please send me the following previous volumes (1-34) at 50% discount on the above rates.
- Payment is enclosed.  Please invoice.  
Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece)
- Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: .....  
 .....  
 Tel: .....  
 Fax: ..... e-mail: .....  
 Signature:..... Date:.....

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

## Special 2015 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2015 on a basis of priority and availability. Effective from January to December 2015).

- **Included in Pubmed, Current Contents and all abstracting and indexing services**
- **Online with Stanford University HighWire Press**
- **Open access articles**

Please complete and send this order form to:  
 ANTICANCER RESEARCH, International Institute of Anticancer Research,  
 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.



Your link to the essential information on cancer research published in the last 33 years.

- 1981-2014
- 34 volumes
- over 116,000 pages
- over 16,900 original articles
- 834 reviews
- over 75,200 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

### Special Subscription Order Form 2015

- I am one of the authors of the article published in Anticancer Research Vol....., pp. ...., year .....
- Please enter my personal subscription to Anticancer Research 2015 (Volume 35) at the special Author's rate of Euro 390.00 (print or online).
- Please send me previous Volume No(s) ..... at Euro 195.00 (print) per volume.
- Please enter my personal combined 2015 subscription to Anticancer Research (Volume 35) and IN VIVO (Volume 29) at Euro 560.00 (print or online).
- My payment is enclosed.
- Please send me an invoice.  
Prices include rapid delivery and insurance. Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece).

Name and address: .....  
 .....  
 .....  
 Tel-Fax: .....  
 e-mail: .....  
 Date and signature: .....

Src Kinase-associated Phosphoprotein2 Expression Is Associated with Poor Prognosis in Non-small Cell Lung Cancer. S. KURANAMI, T. YOKOBORI, A. MOGI, B. ALTAN, T. YAJIMA, R. ONOZATO, Y. AZUMA, M. IJIMA, T. KOSAKA, H. KUWANO ( <i>Maebashi, Japan</i> ) .....	2411
Pathological Patterns of Prostate Biopsy in Men with Fluctuations of Prostate Cancer Gene 3 Score: A Preliminary Report. S. DE LUCA, R. PASSERA, S. CAPPIA, E. BOLLITO, D.F. RANDONE, F. PORPIGLIA ( <i>Orbassano; Torino, Italy</i> ) .....	2417
miR-7 Expression in Serous Ovarian Carcinomas. A. SWIERCZ, M. CHECHLINSKA, J. KUPRYJANCZYK, A. DANSONKA-MIESZKOWSKA, A. REMBISZEWSKA, K. GORYCA, M. KULINCZAK, M. ZAJDEL, M. SROMEK, J.K. SIWICKI ( <i>Warsaw, Poland</i> ) .....	2423
Radiation-induced Second Malignancies. S. MAHMOOD, K. VU, P. TAI, K. JOSEPH, R. KOUL, A. DUBEY, E. YU ( <i>Regina, SK; Edmonton, AB; Winnipeg, MB; London, ON, Canada</i> ) .....	2431
Assessment of Circulating Serum DNA Integrity in Colorectal Cancer Patients. E.E. YÖRÜKER, E. ÖZGÜR, M. KESKIN, N. DALAY, S. HOLDENRIEDER, U. GEZER ( <i>Istanbul, Turkey; Bonn, Germany</i> ) .....	2435
Correlation of HER2 Expression with Clinicopathological Characteristics and Prognosis in Resectable Gastric Cancer. H. OTSU, E. OKI, A. IKAWA-YOSHIDA, H. KAWANO, K. ANDO, S. IDA, Y. KIMURA, S. AISHIMA, H. SAEKI, M. MORITA, S. KOHNOE, Y. ODA, Y. MAEHARA ( <i>Fukuoka; Shizuoka, Japan</i> ) .....	2441
High Expression of Phospho-H2AX Predicts a Poor Prognosis in Colorectal Cancer. Y.-C. LEE, T.C. YIN, Y.-T. CHEN, C.-Y. CHAI, J.Y. WANG, M.-C. LIU, Y.-C. LIN, J.Y. KAN ( <i>Kaohsiung, Taiwan, ROC</i> ) ....	2447
MicroRNA Profile in Site-specific Head and Neck Squamous Cell Cancer. D. KALFERT, M. PESTA, V. KULDA, O. TOPOLCAN, A. RYSKA, P. CELAKOVSKY, J. LACO, M. LUDVIKOVA ( <i>Hradec Kralove; Pilsen, Czech Republic</i> ) .....	2455
The Clinical Significance of Activated p-AKT Expression in Peripheral T-cell Lymphoma. J.Y. HONG, M.E. HONG, M.K. CHOI, W. CHANG, I.-G. DO, J.-S. JO, S.-H. JUNG, S. PARK, S.J. KIM, Y.H. KO, W.S. KIM ( <i>Seoul; Gyeonggi-do, Republic of Korea; Durham, NC, USA</i> ) .....	2465
Long-term Outcome of Living-donor Liver Transplantation for Combined Hepatocellular-cholangiocarcinoma. S. ITOH, T. IKEGAMI, T. YOSHIZUMI, H. WANG, K. TAKEISHI, N. HARIMOTO, Y.-I. YAMASHITA, H. KAWANAKA, S. AISHIMA, K. SHIRABE, Y. MAEHARA ( <i>Fukuoka; Saga, Japan</i> ) .....	2475
Errata .....	2477
Retractions .....	2478

Low-dose Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as an Alternative Therapy for Ovarian Cancer in an Octogenarian Patient. U. GIGER-PABST, W. SOLASS, B. BUERKLE, M.-A. REYMOND, C.B. TEMPFER ( <i>Bochum; Hannover, Germany</i> ) .....	2309
Initial Incomplete Surgery Modifies Prognosis in Advanced Ovarian Cancer Regardless of Subsequent Management. N. BACALBASA, I. BALESCU, S. DIMA, V. HERLEA, L. DAVID, V. BRASOVEANU, I. POPESCU ( <i>Bucharest, Romania</i> ) .....	2315
Expression of Phosphorylated Akt, mTOR and MAPK in Type I Endometrial Carcinoma: Clinical Significance. H.P. KOUREA, M. NIKOLAOU, V. TZELEPI, G. ADONAKIS, D. KARDAMAKIS, V. TSAPANOS, C.D. SCOPA, C. KALOFONOS, G. DECAVALAS ( <i>Patras, Greece</i> ) .....	2321
Risk of Anemia Attributable to Everolimus in Patients with Cancer: A Meta-analysis of Randomized Controlled Trials. R. SHAMEEM, M.S. HAMID, S. WU ( <i>Philadelphia, PA; Detroit, MI; Stony Brook; Northport, NY, USA</i> ) .....	2333
Necessity for Resection of Gastric Gastrointestinal Stromal Tumors $\leq 20$ mm. T. KOGA, Y. HIRAYAMA, S. YOSHIYA, K. TAKETANI, T. NAKANOKO, R. YOSHIDA, R. MINAGAWA, M. KAI, K. KAJIYAMA, K. AKAHOSHI, Y. MAEHARA ( <i>Fukuoka, Japan</i> ) .....	2341
<i>BRAF</i> V600E Mutation in Colorectal Cancer Is Associated with Right-sided Tumours and Iron Deficiency Anaemia. M. SIDERIS, K. ADAMS, J. MOORHEAD, S. DIAZ-CANO, I. BJARNASON, S. PAPAGRIGORIADIS ( <i>London, UK</i> ) .....	2345
Diffusion-weighted Imaging Using 3.0 T MRI as a Possible Biomarker of Renal Tumors. H. MIRKA, E. KORCAKOVA, J. KASTNER, M. HORA, O. HES, P. HOSEK, J. FERDA ( <i>Pilsen, Czech Republic</i> ) .....	2351
Post-chemotherapeutic CEA and CA19-9 Are Prognostic Factors in Patients with Colorectal Liver Metastases Treated with Hepatic Resection After Oxaliplatin-based Chemotherapy. Y. SAKAMOTO, Y. MIYAMOTO, T. BEPPU, H. NITTA, K. IMAI, H. HAYASHI, Y. BABA, N. YOSHIDA, A. CHIKAMOTO, H. BABA ( <i>Kumamoto, Japan</i> ) .....	2359
Clinical Decision-making in Atypical and Suspicious Categories in Fine-needle Aspiration Cytology of the Breast. M. GIPPONI, P. FREGATTI, A. GARLASCHI, M. CALABRESE, P. BACCINI, M. GALLO, F. MURELLI, C. MARGARINO, C. BOBBIO, D. FRIEDMAN ( <i>Genoa, Italy</i> ) .....	2369
Analysis of the Risk Factors for Febrile Neutropenia in Patients with Bone and Soft Tissue Sarcoma. T. AOYAGI, T. MORII, T. TAJIMA, A. YOSHIYAMA, S. ICHIMURA ( <i>Mitaka, Tokyo, Japan</i> ) .....	2375
Critical Evaluation of a Prospective Study of Concurrent Chemoradiotherapy with S-1 for Early Glottic Carcinoma. K. KIMURA, Y. ITOH, T. OKADA, R. NAKAHARA, M. KAWAMURA, S. KUBOTA, J. ITOH, M. HIRAMATSU, Y. FUJIMOTO, T. SHIBATA, S. NAGANAWA ( <i>Aichi, Japan</i> ) .....	2385
Bevacizumab and First-line Chemotherapy for Older Patients with Advanced Colorectal Cancer: Final Results of a Community-based Observational Italian Study. S.E. LUTRINO, F. BERGAMO, M. SCHIRRIPA, G. ROSATI, A. AVALLONE, R. GIAMPIERI, S. CORDIO, M. BERRETTA, F.R. LLIMPE, F.E. PISA, S. LONARDI, F. LOUPAKIS, G. FASOLA, G. APRILE ( <i>Udine; Padova; Pisa; Potenza; Napoli; Ancona; Catania; Aviano; Bologna, Italy</i> ) .....	2391
Impact of Postoperative Complications on Survival and Recurrence in Pancreatic Cancer. T. AOYAMA, M. M. URAKAWA, Y. KATAYAMA, K. YAMAOKU, A. KANAZAWA, A. HIGUCHI, M. SHIOZAWA, M. MORIMOTO, T. YOSHIKAWA, N. YAMAMOTO, Y. RINO, M. MASUDA, S. MORINAGA ( <i>Yokohama, Japan</i> ) .....	2401

Agreement Between Hopelessness/Helplessness and Montgomery-Asberg Depression Rating Scale in Healthy Individuals and in Patients with Benign Breast Disease and Breast Cancer: A Prospective Case-Control Study in Finland. M. ESKELINEN, R. KORHONEN, T. SELANDER, P. OLLONEN ( <i>Kuopio, Finland</i> ) .....	2215
Preoperative Systemic and Intraperitoneal Chemotherapy Consisting of S-1, Cisplatin and Docetaxel in Patients with Marginally Resectable Gastric Cancer. Y. KUROKAWA, T. HAMAKAWA, Y. MIYAZAKI, T. TAKAHASHI, M. YAMASAKI, H. MIYATA, K. NAKAJIMA, S. TAKIGUCHI, M. MORI, Y. DOKI ( <i>Osaka, Japan</i> ).....	2223
Prognostic Factors and Survival in Patients Treated Surgically for Primary and Recurrent Uterine Leiomyosarcoma: A Single Center Experience. N. BACALBASA, I. BADESCU, S. DIMA, V. BRASOVEANU, I. POPESCU ( <i>Bucharest, Romania</i> ).....	2229
High Interleukin-6 mRNA Expression Is a Predictor of Relapse in Colon Cancer. J. OLSEN, L.T. KIRKEBY, J. OLSEN, S. EIHMOLM, P. JESS, I. GÖGENUR, J.T. TROELSEN ( <i>Roskilde; Copenhagen, Denmark</i> ) .....	2235
The Role of <sup>18</sup> F-FDG Accumulation and Arterial Enhancement as Biomarkers in the Assessment of Typing, Grading and Staging of Hepatocellular Carcinoma Using <sup>18</sup> F-FDG-PET/CT with Integrated Dual-phase CT Angiography. J. FERDA, E. FERDOVÁ, J. BAXA, B. KREUZBERG, O. DAUM, V. TŘEŠKA, T. SKALICKÝ ( <i>Pilsen, Czech Republic</i> ) .....	2241
Efficacy of 18-FDG PET-CT Dual-phase Scanning for Detection of Lymph Node Metastasis in Gynecological Cancer. Y. NOGAMI, K. BANNO, H. IRIE, M. IIDA, Y. MASUGI, K. MURAKAMI, D. AOKI ( <i>Tokyo, Japan</i> ) .....	2247
Bevacizumab and Postoperative Wound Complications in Patients with Liver Metastases of Colorectal Cancer. H. UTSUMI, Y. HONMA, K. NAGASHIMA, S. IWASA, A. TAKASHIMA, K. KATO, T. HAMAGUCHI, Y. YAMADA, Y. SHIMADA, Y. KISHI, S. NARA, M. ESAKI, K. SHIMADA ( <i>Tokyo; Chiba, Japan</i> ) .....	2255
Gastric Cancer Patients with End-stage Renal Disease Who Underwent Radical Gastrectomy. Y.-Y. LIU, C.-Y. TSAI, C.-N. YEY, K.-C. CHIANG, S.-Y. WANG, C.-T. CHENG, C.-H. LIAO, J.-T. HSU, T.-S. YEY, Y.-Y. JAN, M.-F. CHEN ( <i>Taipei, Taiwan, ROC</i> ) .....	2263
Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. H. NAGAI, T. MUKOZU, Y. OGINO, D. MATSUI, T. MATSUI, N. WAKUI, K. MOMIYAMA, Y. IGARASHI, Y. SUMINO, K. HIGAI ( <i>Tokyo; Funabashi, Japan</i> ).....	2269
Human Leukocyte Antigen (HLA)-E and HLA-F Expression in Gastric Cancer. S. ISHIGAMI, T. ARIGAMI, H. OKUMURA, Y. UCHIKADO, Y. KITA, H. KURAHARA, K. MAEMURA, Y. KIJIMA, Y. ISHIHARA, K. SASAKI, Y. UENOSONO, S. NATSUGOE ( <i>Kagoshima, Japan</i> ) .....	2279
Clinical Significance of CD155 Expression in Human Pancreatic Cancer. S. NISHIWADA, M. SHO, S. YASUDA, K. SHIMADA, I. YAMATO, T. AKAHORI, S. KINOSHITA, M. NAGAI, N. KONISHI, Y. NAKAJIMA ( <i>Kashihara, Japan</i> ) .....	2287
Hyperthermia Combined with Chemotherapy for Patients with Residual or Recurrent Oesophageal Cancer After Definitive Chemoradiotherapy. S. NISHIMURA, H. SAEKI, T. NAKANOKO, Y. KASAGI, Y. TSUDA, Y. ZAITSU, K. ANDO, Y. NAKASHIMA, Y. IMAMURA, K. OHGAKI, E. OKI, S. OHGA, K. NAKAMURA, M. MORITA, Y. MAEHARA ( <i>Fukuoka, Japan</i> ) .....	2299
Histopathologic Features Predictive of Aggressiveness of Post-transplant Cutaneous Squamous-cell Carcinomas. J. KANITAKIS, G. KARAYANNOPOULOU, A. ROUX, S. EUVRARD ( <i>Lyon, France; Thessaloniki, Greece</i> ).....	2305

*Clinical studies*

Synchronous Quadruple Primary Neoplasms: Glioblastoma, Neuroendocrine Tumor, Schwannoma and Sessile Serrated Adenoma in a Patient with History of Prostate Cancer. S. GRACE, R. MUZAFFAR, J. VEERAPONG, S. ALKAADE, N. PODDAR, N. PHILLIPS, M. GUZMAN, J. BATANIAN, C. VOGLER, J.-P. LAI ( <i>Saint Louis, MO, USA</i> ) .....	2121
Extraskelatal Osteosarcoma in Norway, Between 1975 and 2009, and a Brief Review of the Literature. K. BERNER, B. BJERKEHAGEN, Ø.S. BRULAND, A. BERNER ( <i>Oslo, Norway</i> ) .....	2129
Early Effects of Adjuvant Breast Cancer Radiotherapy on Right Ventricular Systolic and Diastolic Function. S.S. TUOHINEN, T. SKYTTÄ, V. VIRTANEN, T. LUUKKAALA, P.-L. KELLOKUMPU-LEHTINEN, P. RAATIKAINEN ( <i>Tampere; Jyväskylä, Finland</i> ) .....	2141
Volumetric-modulated Arc Therapy with Vaginal Cuff Simultaneous Integrated Boost as an Alternative to Brachytherapy in Adjuvant Irradiation for Endometrial Cancer: A Prospective Study. F. ALONGI, R. MAZZOLA, F. RICCHETTI, S. FERSINO, N. GIAJ LEVRA, A. FIORENTINO, S. NACCARATO, G. SICIGNANO, G. DI PAOLA, R. RUGGIERI, S. GORI, M. CECCARONI ( <i>Verona; Palermo, Italy</i> ) .....	2149
Scoring System Based on Tumor Markers and Child-Pugh Classification for HCC Patients who Underwent Liver Resection. S. NAKAGAWA, H. HAYASHI, H. NITTA, H. OKABE, K. SAKAMOTO, T. HIGASHI, H. KUROKI, K. IMAI, D. HASHIMOTO, Y. SAKAMOTO, A. CHIKAMOTO, T. BEPPU, H. BABA ( <i>Kumamoto, Japan</i> ) .....	2157
Long-term Control in a Patient with Refractory Multiple Myeloma by Oral Cyclophosphamide and Dexamethasone. N. STEINER, D. NACHBAUR, P. KÖNIG, W. WILLENBACHER, E. GUNSILIUS ( <i>Innsbruck, Austria</i> ) .....	2165
Multiple Visceral Resection for Giant Non-Secretory Adrenocortical Carcinoma in an Elderly Patient: A Case Report. N. BACALBASA, D. TERZEA, V. JIANU, M. MARCU, C. STOICA, I. BALESCU ( <i>Bucharest, Romania</i> ) .....	2169
Post-void Residual Urinary Volume Is an Independent Predictor of Biopsy Results in Men at Risk for Prostate Cancer. L. CORMIO, G. LUCARELLI, G.S. NETTI, G. STALLONE, O. SELVAGGIO, F. TROIANO, G. DI FINO, F. SANGUEDOLCE, P. BUFO, G. GRANDALIANO, G. CARRIERI ( <i>Foggia, Italy</i> ) .....	2175
Epirubicin plus Paclitaxel Regimen as Second-line Treatment of Patients with Small-cell Lung Cancer. G. PASELLO, P. CARLI, F. CANOVA, L. BONANNO, V. POLO, G. ZAGO, L. URSO, P. CONTE, A. FAVARETTO ( <i>Padova; Treviso, Italy</i> ) .....	2183
Impact of Age on Early Surgical Outcomes of Laparoscopy-assisted Gastrectomy with Suprapancreatic Nodal Dissection for Clinical Stage I Gastric Cancer. T. KOSUGA, D. ICHIKAWA, K. OKAMOTO, S. KOMATSU, H. KONISHI, H. TAKESHITA, A. SHIOZAKI, H. FUJIWARA, R. MORIMURA, H. IKOMA, Y. MURAYAMA, Y. KURIU, M. NAKANISHI, C. SAKAKURA, E. OTSUJI ( <i>Kyoto, Japan</i> ) .....	2191
Nephroprotective Effects of Hydration with Magnesium in Patients with Cervical Cancer Receiving Cisplatin. Y. YAMAMOTO, K. WATANABE, I. TSUKIYAMA, H. MATSUSHITA, H. YABUSHITA, K. MATSUURA, A. WAKATSUKI ( <i>Aichi, Japan</i> ) .....	2199
VEGF in Patients with Advanced Hepatocellular Carcinoma Receiving Intra-arterial Chemotherapy. D. MATSUI, H. NAGAI, T. MUKOZU, Y. OGINO, Y. SUMINO ( <i>Tokyo, Japan</i> ) .....	2205
Association of Liver Steatosis with Colorectal Cancer and Adenoma in Patients with Metabolic Syndrome. E. FIORI, A. LAMAZZA, E. DE MASI, A. SCHILLACI, D. CROCETTI, A. ANTONIOZZI, A.V. STERPETTI, G. DE TOMA ( <i>Rome, Italy</i> ) .....	2211



Dual Expression of shAkt1 and Pcd4 Suppresses Lung Tumorigenesis in <i>K-ras<sup>LA1</sup></i> Mice. S.-H. HONG, J.-H. LEE, H.-L. JIANG, J.-E. KIM, A.Y. LEE, S. KIM, C.-S. CHO, M.-H. CHO ( <i>Seoul; Suwon; Pyeongchang-gun, Republic of Korea; Nanjing, PR China</i> ) .....	2015
Gene Expression Analysis for Evaluation of Potential Biomarkers in Hepatocellular Carcinoma. H. HASS, J. JOBST, M. SCHEURLLEN, U. VOGEL, O. NEHLS ( <i>Scheidegg; Reutlingen; Wuerzburg; Tuebingen; Stuttgart, Germany</i> ) .....	2021
Search for New Genetic Biomarkers in Poorly Differentiated and Anaplastic Thyroid Carcinomas Using Next Generation Sequencing. V. SYKOROVA, S. DVORAKOVA, J. VCELAK, E. VACLAVIKOVA, T. HALKOVA, D. KODETOVA, P. LASTUVKA, J. BETKA, P. VLCEK, M. REBOUN, R. KATRA, B. BENDLOVA ( <i>Prague, Czech Republic</i> ) .....	2029
The Role of MicroRNAs in Thyroid Carcinomas. S. FORTE, C. LA ROSA, V. PECCE, F. ROSIGNOLO, L. MEMEO ( <i>Viagrande; Rome, Italy</i> ) .....	2037
Effect of Perioperative Treatment with a Hypoxia-inducible Factor-1-alpha Inhibitor in an Orthotopic Surgical Mouse Model of Thyroid Cancer. W. CHA, D.-W. KIM, S.D. KIM, E.-H. JEON, W.-J. JEONG, S.-H. AHN ( <i>Busan; Seongnam; Seoul, Republic of Korea</i> ) .....	2049
Dysregulation of MicroRNAs in Angioimmunoblastic T-Cell Lymphoma. K. REDDEMANN, D. GOLLA, A. SCHILLERT, J. KNIEF, C. KUEMPERS, J. RIBBAT-IDEL, S. BER, J. SCHEMME, V. BERNARD, N. GEBAUER, A.C. FELLER, C. THORNS ( <i>Luebeck, Germany</i> ) .....	2055
Structural Changes in Albumin Are a Possible Mechanism for Fluctuation of Cefazolin and Ibuprofen Plasma Protein Binding in Rats with Carcinogen-induced Osteosarcoma. Y. ITAKURA, S. TAGA, C. IWATA, H. TERAMACHI, K.-I. MIYAMOTO, H. TSUCHIYA, T. WADA, R. MATSUSHITA ( <i>Aichi; Kanazawa; Gifu, Japan</i> ) .....	2063
The Relationship of CD133, Histone Deacetylase 1 and Thrombospondin-1 in Gastric Cancer. S. ETO, K. YOSHIKAWA, M. SHIMADA, J. HIGASHIJIMA, T. TOKUNAGA, T. NAKAO, M. NISHI, C. TAKASU, H. SATO, N. KURITA ( <i>Tokushima, Japan</i> ) .....	2071
Gallic Acid Induces DNA Damage and Inhibits DNA Repair-associated Protein Expression in Human Oral Cancer SCC-4 Cells. S.-W. WENG, S.-C. HSU, H.-C. LIU, B.-C. JI, J.-C. LIEN, F.-S. YU, K.-C. LIU, K.-C. LAI, J.-P. LIN, J.-G. CHUNG ( <i>Taichung; Changhua; Tainan, Taiwan, ROC</i> ) .....	2077
Novel <i>In Vitro</i> Platform to Investigate Myotube Atrophy. C. OELKRUG, K. HORN, G.R. MAKERT, A. SCHUBERT ( <i>Leipzig, Germany</i> ) .....	2085
Aberrant Glycosylation of $\alpha_v\beta_3$ Integrin is Associated with Melanoma Progression. E. POCHEĆ, M. BUBKA, M. RYDLEWSKA, M. JANIK, M. POKRYWKA, A. LITYŃSKA ( <i>Krakow, Poland</i> ) .....	2093
Substituted Steroidal Compounds Containing Amino and Amido Groups Reverse Multidrug Resistance of Mouse T-Lymphoma and Two Human Prostate Cancer Cell Lines <i>In Vitro</i> . Á. CSONKA, S. HAMDOUN, G. SPENGLER, A. MARTINS, I. VINCZE, T. EFFERTH, J. MOLNÁR ( <i>Szeged, Hungary; Lisbon, Portugal; Mainz, Germany</i> ) .....	2105
Clinical and Prognostic Significance of Survivin, AKT and VEGF in Primary Mucosal Oral Melanoma. O. SIMONETTI, G. LUCARINI, C. RUBINI, R. LAZZARINI, R. DI PRIMIO, A. OFFIDANI ( <i>Ancona, Italy</i> ) .....	2113

Proliferating Fibroblasts and HeLa Cells Co-cultured <i>In Vitro</i> Reciprocally Influence Growth Patterns, Protein Expression, Chromatin Features and Cell Survival. J.G. DELINASIOS, F. ANGELI, G. KOUMAKIS, S. KUMAR, W.-H. KANG, G. SICA, F. IACOPINO, G. LAMA, S. LAMPRECHT, I. SIGAL-BATIKOFF, G.T. TSANGARIS, C.D. FARFARELOS, M.C. FARFARELOS, E. VAIRAKTARIS, S. VASSILIOU, G.J. DELINASIOS ( <i>Kapandriti; Athens; Piraeus, Greece; Manchester, UK; Rome, Italy; Beersheba, Israel</i> ) .....	1881
Comparative Characterization of Stem Cell Marker Expression, Metabolic Activity and Resistance to Doxorubicin in Adherent and Spheroid Cells Derived from the Canine Prostate Adenocarcinoma Cell Line CT1258. W. LIU, M. MOULAY, S. WILLENBROCK, C. ROOLF, C. JUNGHANSS, A. NGENAZAHAYO, I. NOLTE, H.M. ESCOBAR ( <i>Hannover; Rostock, Germany</i> ) .....	1917
Quantitative Structure–Activity Relationship and Molecular Docking of Artemisinin Derivatives to Vascular Endothelial Growth Factor Receptor 1. M.E.M. SAEED, O. KADIOGLU, E.-J. SEO, H.J. GRETEN, R. BRENK, T. EFFERTH ( <i>Mainz; Heidelberg, Germany; Porto, Portugal</i> ) .....	1929
Formamidinodoxorubicins Are more Potent than Doxorubicin as Apoptosis Inducers in Human Breast Cancer Cells. A. MARCZAK, M. DENEL-BOBROWSKA, M. ŁUKAWSKA, I. OSZCZAPOWICZ ( <i>Lodz; Warsaw, Poland</i> ) .....	1935
Resistance to Gemcitabine in the Pancreatic Cancer Cell Line KLM1-R Reversed by Metformin Action. B. BARON, Y. WANG, S.-I. MAEHARA, Y. MAEHARA, Y. KURAMITSU, K. NAKAMURA ( <i>Ube; Shunan-shi; Fukuoka, Japan; Msida, Malta</i> ) .....	1941
Targeting mTOR and AREG with Everolimus, Sunitinib and Sorafenib in HPV-positive and -negative SCC. C. ADERHOLD, A. FABER, C. UMBREIT, R. BIRK, C. WEISS, J.U. SOMMER, K. HÖRMANN, J.D. SCHULTZ ( <i>Mannheim, Germany</i> ).....	1951
Carbonyl Levels and Survival Rates in Oral Cancer Cells Exposed to Cigarette Smoke. E. KRAYZLER, R.M. NAGLER ( <i>Haifa, Israel</i> ) .....	1961
Sorafenib Inhibits Migration and Invasion of Hepatocellular Carcinoma Cells Through Suppression of Matrix Metalloproteinase Expression. T.-Y. HA, S. HWANG, K.-M. MOON, Y.-J. WON, G.-W. SONG, N. KIM, E. TAK, B.-Y. RYOO, H.-N. HONG ( <i>Seoul; Yangsan, Republic of Korea</i> ).....	1967
The Therapeutic Effect of Photon Irradiation on Viable Glioblastoma Cells Is Reinforced by Hyperbaric Oxygen. H. BÜHLER, G.L. STROHM, P. NGUEMGO-KOUAM, H. LAMM, K. FAKHRIAN, I.A. ADAMIETZ ( <i>Herne; Hannover, Germany</i> ) .....	1977
Synergistic Effect of Sorafenib and Vitamin K on Suppression of Hepatocellular Carcinoma Cell Migration and Metastasis. T.-Y. HA, S. HWANG, H.-N. HONG, Y.-I. CHOI, S.-Y. YOON, Y.-J. WON, G.-W. SONG, N. KIM, E. TAK, B.-Y. RYOO ( <i>Seoul; Busan; Gyeonggi-do, Republic of Korea</i> ) .....	1985
The Novel CA IX Inhibition Antibody chKM4927 Shows Anti-tumor Efficacy <i>In Vivo</i> . A. YAMAGUCHI, K. USAMI, M. SHIMABE, K. HASEGAWA, M. ASADA, K. MOTOKI, T. TAHARA, K. MASUDA ( <i>Tokyo, Japan</i> ) .....	1997
Afatinib is Especially Effective Against Non-small Cell Lung Cancer Carrying an <i>EGFR</i> Exon 19 Deletion. E. BANNO, Y. TOGASHI, Y. KOBAYASHI, H. HAYASHI, T. MITSUDOMI, K. NISHIO ( <i>Osaka, Japan</i> ) .....	2005
Population Stratification Effect on Cancer Susceptibility in an Admixed Population from Brazilian Amazon. P.C. VIEIRA, R.M.R. BURBANO, D.C.R.O. FERNANDES, R.C. MONTENEGRO, S.E.B. DOS SANTOS, V.A. SORTICA, P.P. ASSUMPCÃO, Â.K.C. RIBEIRO-DOS-SANTOS, A.A. CARVALHO, N.P.C. DOS SANTOS ( <i>Belém, Pará, Brazil</i> ).....	2009